You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,469,030

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,469,030 protect, and when does it expire?

Patent 6,469,030 protects ENTEREG and is included in one NDA.

This patent has nineteen patent family members in fourteen countries.

Summary for Patent: 6,469,030
Title: Methods for the treatment and prevention of ileus
Abstract:Methods for the treatment and/or prevention of ileus are disclosed. The methods comprise administering to a patient an effective amount of a peripheral mu opioid antagonist compound. Preferred compounds for use in the methods include piperidine-N-alkylcarboxylates.
Inventor(s): Farrar; John J. (Chester Springs, PA), Schied; Peter J. (Southampton, PA), Schmidt; William K. (Newark, DE), Carpenter; Randall L. (Waban, MA)
Assignee: Adolor Corporation (Exton, PA)
Application Number:09/725,708
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,469,030
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 6,469,030

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes   Start Trial   Start Trial A METHOD OF TREATING OR PREVENTING ILEUS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,469,030

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 432076   Start Trial
Australia 2005203041   Start Trial
Australia 3970501   Start Trial
Australia 780738   Start Trial
Canada 2393141   Start Trial
Cyprus 1109264   Start Trial
Germany 60042282   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.